Current use of pimobendan in canine patients with heart disease.
Pimobendan is a drug with both inotropic and vasodilatory properties and is widely used for the treatment of heart failure in dogs. The best evidence regarding its efficacy is derived from several clinical studies of dogs with the two most common conditions that result in heart failure: dilated cardiomyopathy (DCM) and degenerative mitral valve disease (DMVD). The main studies addressing the effectiveness of pimobendan in dogs with DCM and DVMD are discussed in this article.
Boswood
Adrian
A
Department of Veterinary Clinical Sciences, The Royal Veterinary College, Herts AL9 7TA, UK. aboswood@rvc.ac.uk
D000818:Animals; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy / Q000662:veterinary; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D006331:Heart Diseases / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D008944:Mitral Valve Insufficiency; D011724:Pyridazines / Q000627:therapeutic use*; D016896:Treatment Outcome
D002316:Cardiotonic Agents; D011724:Pyridazines; C041648:pimobendan